MA43794A - Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie - Google Patents
Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapieInfo
- Publication number
- MA43794A MA43794A MA043794A MA43794A MA43794A MA 43794 A MA43794 A MA 43794A MA 043794 A MA043794 A MA 043794A MA 43794 A MA43794 A MA 43794A MA 43794 A MA43794 A MA 43794A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- immunotherapy
- predicting
- neoantigens
- tumor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention concerne des procédés de prédiction de l'utilité de peptides ou de polypeptides tels que des épitopes de lymphocytes t pour l'immunothérapie, par exemple pour la vaccination. En particulier, la présente invention concerne des procédés pour prédire si des peptides ou des polypeptides tels que des antigènes ou des épitopes associés à une tumeur, en particulier des néoantigènes ou néoépitopes associés à une tumeur, sont immunogènes et, en particulier, utiles pour l'immunothérapie, par exemple pour la vaccination. Les procédés selon l'invention peuvent être utilisés en particulier pour fournir des vaccins qui sont spécifiques d'une tumeur d'un patient et, donc, dans le contexte de vaccins anticancéreux personnalisés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/060897 WO2017194170A1 (fr) | 2016-05-13 | 2016-05-13 | Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie |
| PCT/EP2017/061196 WO2017194610A1 (fr) | 2016-05-13 | 2017-05-10 | Procédés de prédiction de l'utilité de protéines ou de fragments de protéines pour l'immunothérapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43794A true MA43794A (fr) | 2019-03-20 |
| MA43794B1 MA43794B1 (fr) | 2020-12-31 |
Family
ID=55971007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43794A MA43794B1 (fr) | 2016-05-13 | 2017-05-10 | Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12153041B2 (fr) |
| EP (3) | EP3792628B1 (fr) |
| JP (5) | JP7529381B2 (fr) |
| KR (3) | KR20240146087A (fr) |
| CN (1) | CN109073637A (fr) |
| AU (2) | AU2017264546B2 (fr) |
| BR (1) | BR112018073221A2 (fr) |
| CA (1) | CA3022654A1 (fr) |
| CY (1) | CY1123520T1 (fr) |
| DK (2) | DK3455625T3 (fr) |
| ES (2) | ES2826480T3 (fr) |
| FI (1) | FI3792628T3 (fr) |
| HR (2) | HRP20201671T1 (fr) |
| HU (2) | HUE052240T2 (fr) |
| IL (2) | IL300841A (fr) |
| LT (2) | LT3455625T (fr) |
| MA (1) | MA43794B1 (fr) |
| MD (1) | MD3455625T2 (fr) |
| MX (2) | MX393653B (fr) |
| PL (2) | PL3455625T3 (fr) |
| PT (2) | PT3792628T (fr) |
| RS (2) | RS61071B1 (fr) |
| SG (1) | SG11201808495SA (fr) |
| SI (2) | SI3455625T1 (fr) |
| SM (2) | SMT202400232T1 (fr) |
| WO (2) | WO2017194170A1 (fr) |
| ZA (1) | ZA201805809B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017205270B2 (en) | 2016-01-08 | 2024-01-18 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| WO2017194170A1 (fr) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie |
| WO2018222433A2 (fr) | 2017-05-30 | 2018-12-06 | Nant Holdings Ip, Llc | Enrichissement de cellules tumorales circulantes à l'aide de néo-épitopes |
| CN111788214B (zh) * | 2018-02-15 | 2021-06-22 | 国立大学法人旭川医科大学 | 癌症抗原肽 |
| EP3826669A2 (fr) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Vaccins standard contre le cancer |
| IL280112B2 (en) | 2018-07-26 | 2025-11-01 | Curevac Netherlands B V | Cancer vaccines for breast cancer |
| CN109021062B (zh) * | 2018-08-06 | 2021-08-20 | 倍而达药业（苏州）有限公司 | 一种肿瘤新抗原的筛选方法 |
| CN111621564B (zh) * | 2019-02-28 | 2022-03-25 | 武汉大学 | 一种鉴定有效肿瘤新抗原的方法 |
| CN113711239A (zh) * | 2019-03-06 | 2021-11-26 | 磨石生物公司 | 利用ii类mhc模型鉴别新抗原 |
| CN110534156B (zh) * | 2019-09-02 | 2022-06-17 | 深圳市新合生物医疗科技有限公司 | 一种提取免疫治疗新抗原的方法及系统 |
| CN111487399B (zh) * | 2020-03-26 | 2021-09-17 | 湖南师范大学 | 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用 |
| AU2021461416A1 (en) | 2021-08-24 | 2024-02-22 | BioNTech SE | In vitro transcription technologies |
| WO2024083345A1 (fr) | 2022-10-21 | 2024-04-25 | BioNTech SE | Procédés et utilisations associés à des compositions liquides |
| WO2025202937A1 (fr) | 2024-03-26 | 2025-10-02 | BioNTech SE | Vaccins anticancéreux |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| CA2405363A1 (fr) * | 2000-04-28 | 2001-11-08 | Ctl Immunotherapies Corp. | Synchronisation d'epitopes dans des cellules presentant des antigenes |
| JP2004502946A (ja) | 2000-07-10 | 2004-01-29 | ゼンコー | 改変された免疫原性を有するタンパク質ライブラリーを設計するためのタンパク質設計オートメーション |
| CA2417570C (fr) * | 2000-07-31 | 2010-12-07 | Kyogo Itoh | Activation des lymphocytes t specifiques des tumeurs par antigenes peptidiques |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
| CA2603191A1 (fr) * | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Vaccins contre le cancer et methodes therapeutiques |
| JP2009273377A (ja) | 2008-05-12 | 2009-11-26 | Igaku Seibutsugaku Kenkyusho:Kk | Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法 |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| AU2010228108A1 (en) | 2009-03-23 | 2011-11-03 | The Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for modulating an immune response |
| US20110274723A1 (en) * | 2009-10-23 | 2011-11-10 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| HRP20250981T1 (hr) | 2011-05-24 | 2025-10-24 | BioNTech SE | Individualizirana cjepiva protiv raka |
| WO2012159643A1 (fr) | 2011-05-24 | 2012-11-29 | Biontech Ag | Vaccins individualisés pour le cancer |
| US9266922B2 (en) * | 2011-06-01 | 2016-02-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antigen peptide and uses thereof |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| WO2017194170A1 (fr) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie |
| US20210113673A1 (en) | 2017-04-19 | 2021-04-22 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| AU2018279627B2 (en) | 2017-06-09 | 2023-08-10 | Seattle Project Corp. | Neoantigen identification, manufacture, and use |
| EP3679578A4 (fr) | 2017-09-05 | 2021-06-30 | Gritstone Oncology, Inc. | Identification de néoantigène pour une thérapie par lymphocytes t |
| ES3029080T3 (en) | 2017-10-10 | 2025-06-23 | Seattle Project Corp | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| TW202000693A (zh) | 2018-02-27 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 利用泛對偶基因（pan-allele）模型之新抗原鑑別 |
-
2016
- 2016-05-13 WO PCT/EP2016/060897 patent/WO2017194170A1/fr not_active Ceased
-
2017
- 2017-05-10 KR KR1020247031632A patent/KR20240146087A/ko active Pending
- 2017-05-10 EP EP20193183.9A patent/EP3792628B1/fr active Active
- 2017-05-10 MD MDE20190332T patent/MD3455625T2/ro unknown
- 2017-05-10 RS RS20201233A patent/RS61071B1/sr unknown
- 2017-05-10 WO PCT/EP2017/061196 patent/WO2017194610A1/fr not_active Ceased
- 2017-05-10 JP JP2018559794A patent/JP7529381B2/ja active Active
- 2017-05-10 SM SM20240232T patent/SMT202400232T1/it unknown
- 2017-05-10 BR BR112018073221-4A patent/BR112018073221A2/pt unknown
- 2017-05-10 PT PT201931839T patent/PT3792628T/pt unknown
- 2017-05-10 KR KR1020227002915A patent/KR20220020993A/ko not_active Ceased
- 2017-05-10 SI SI201730466T patent/SI3455625T1/sl unknown
- 2017-05-10 LT LTEP17726208.6T patent/LT3455625T/lt unknown
- 2017-05-10 LT LTEP20193183.9T patent/LT3792628T/lt unknown
- 2017-05-10 PL PL17726208T patent/PL3455625T3/pl unknown
- 2017-05-10 SI SI201731526T patent/SI3792628T1/sl unknown
- 2017-05-10 EP EP17726208.6A patent/EP3455625B1/fr active Active
- 2017-05-10 KR KR1020187032652A patent/KR102358620B1/ko active Active
- 2017-05-10 HU HUE17726208A patent/HUE052240T2/hu unknown
- 2017-05-10 CN CN201780026579.0A patent/CN109073637A/zh active Pending
- 2017-05-10 ES ES17726208T patent/ES2826480T3/es active Active
- 2017-05-10 DK DK17726208.6T patent/DK3455625T3/da active
- 2017-05-10 MA MA43794A patent/MA43794B1/fr unknown
- 2017-05-10 EP EP24171718.0A patent/EP4411376A3/fr active Pending
- 2017-05-10 US US16/301,019 patent/US12153041B2/en active Active
- 2017-05-10 RS RS20240614A patent/RS65568B1/sr unknown
- 2017-05-10 CA CA3022654A patent/CA3022654A1/fr active Pending
- 2017-05-10 PL PL20193183.9T patent/PL3792628T3/pl unknown
- 2017-05-10 SG SG11201808495SA patent/SG11201808495SA/en unknown
- 2017-05-10 DK DK20193183.9T patent/DK3792628T3/da active
- 2017-05-10 PT PT177262086T patent/PT3455625T/pt unknown
- 2017-05-10 ES ES20193183T patent/ES2980781T3/es active Active
- 2017-05-10 SM SM20200622T patent/SMT202000622T1/it unknown
- 2017-05-10 HR HRP20201671TT patent/HRP20201671T1/hr unknown
- 2017-05-10 HR HRP20240704TT patent/HRP20240704T1/hr unknown
- 2017-05-10 AU AU2017264546A patent/AU2017264546B2/en active Active
- 2017-05-10 HU HUE20193183A patent/HUE067497T2/hu unknown
- 2017-05-10 MX MX2018013081A patent/MX393653B/es unknown
- 2017-05-10 IL IL300841A patent/IL300841A/en unknown
- 2017-05-10 FI FIEP20193183.9T patent/FI3792628T3/fi active
-
2018
- 2018-08-29 ZA ZA2018/05809A patent/ZA201805809B/en unknown
- 2018-10-25 MX MX2022007902A patent/MX2022007902A/es unknown
- 2018-10-29 IL IL262680A patent/IL262680B2/en unknown
-
2020
- 2020-10-14 CY CY20201100969T patent/CY1123520T1/el unknown
-
2022
- 2022-02-16 JP JP2022021751A patent/JP2022081492A/ja active Pending
- 2022-07-27 AU AU2022209286A patent/AU2022209286A1/en active Pending
-
2024
- 2024-03-21 JP JP2024045130A patent/JP2024096712A/ja active Pending
- 2024-04-23 JP JP2024069742A patent/JP2024112805A/ja active Pending
- 2024-06-27 JP JP2024103724A patent/JP2024160216A/ja active Pending
- 2024-10-18 US US18/920,525 patent/US20250244311A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43794A (fr) | Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie | |
| MX2020012130A (es) | Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2. | |
| PH12018502601A1 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| GT201700162A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| MY200886A (en) | Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens | |
| NZ750005A (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| MA31093B1 (fr) | Vaccin | |
| MX2024014422A (es) | Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia | |
| MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
| MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| CR20200434A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 5. 2018-74) | |
| BR112018002844A2 (pt) | receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos | |
| DK1694706T3 (da) | Modificeret anti-CD52-antistof | |
| PE20191847A1 (es) | Receptores de antigenos quimericos que se dirigen a flt3 | |
| MA40476B1 (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
| MA40929A (fr) | Procédé de production d'anticorps à affinité élevée | |
| MX2025005092A (es) | Anticuerpo anti-trem2 y usos del mismo | |
| PH12022550035A1 (en) | Antibodies which bind to cancer cells and target radionuclides to said cells | |
| ZA202108422B (en) | Anti-cd25 for tumour specific cell depletion | |
| MX2023009434A (es) | Anticuerpos contra cd112r y usos de los mismos. | |
| WO2023129870A3 (fr) | Anticorps reconnaissant spécifiquement c5ar1 et utilisations associées | |
| CR20230385A (es) | Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células | |
| WO2021016534A3 (fr) | Polypeptides antigéniques et leurs procédés d'utilisation | |
| CR20200474A (es) | PÉPTIDOS Y COMBINACIONES DE PÉPTIDOS NOVEDOSOS PARA US USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522) |